[Skip to Navigation]
Views 1,165
Citations 0
Comment & Response
August 19, 2020

Does Degarelix Hold Potential for the Treatment of Pedophilic Disorder?

Author Affiliations
  • 1State University of New York (SUNY) Downstate Health Sciences University, Brooklyn, New York
JAMA Psychiatry. 2020;77(10):1084-1085. doi:10.1001/jamapsychiatry.2020.2594

To the Editor The study by Landgren et al1 aimed at generating evidence to use degarelix for the treatment of pedophilic disorder in men. Notwithstanding the importance of the topic covered and ingenious method of assigning temporary identification numbers to the participants, there were some methodologic issues that deserve attention. The study population was men who were required to self-report their urges and behaviors, some of which were reportable by law if revealed in their entirety. The study equated the presence of sexual desire and pedophilic attraction (part of the primary outcome) with sexually abusive behavior, which threatens the validity of the study. Also, the reduction of testosterone level is unusually prolonged, and the described effect does not match the previously discovered pharmacodynamic properties of degarelix.2 Testosterone reduction beyond 1 month of single-dose treatment is unusual for degarelix, which hints at the possibility of additional factors playing a role, eg, other medications not reported by the participants. Moreover, while the authors inquired about previous manic episode, current hypomania, and psychotic symptoms, it was not clear if they assessed any change in regimen or dose of psychiatric medications during the follow-up period. Such changes, if present, could have an additive role in improving pedophilic urges.3-5

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words